Has invested 350 million yuan in Hengrui's topical JAK1 inhibitor phase II clinical success

On October 11, Hengrui Medicine announced that the double-blind, excipient-controlled, phase II/III phase II/III seamless adaptive design clinical study RSJ10431 (MARBLE23) of SHR0302 alkali ointment for the treatment of atopic dermatitis developed by its subsidiary Ruishi Biotechnology Among them, the 0.

The results of the study showed that patients who received topical 0.

From: Corporate Announcement

This is the first domestically-made innovative drug of JAK1 inhibitor for external use that has entered clinical trials in China

The RSJ10431 study that reached the end point was led by Professor Xu Jinhua from Huashan Hospital of Fudan University as the main investigator.

Ruishi Biology will communicate with the drug supervision department regarding the above-mentioned research results and follow-up clinical development plans, and initiate SHR0302 base ointment for the phase III clinical treatment of mild to moderate atopic dermatitis as soon as possible

Atopic dermatitis is a chronic inflammatory skin disease with complex lesions and diverse clinical manifestations and symptoms.

SHR0302 alkali ointment is a topical, highly selective JAK1 inhibitor, which can exert anti-inflammatory and immune-suppressing biological effects by inhibiting JAK1 signal transduction